France's Ipsen Q3 sales rise 28% driven by core portfolio

Overview

• France-based biopharma's Q3 sales rose 28%, driven by core portfolio

• Company raised full-year 2026 sales growth and margin guidance

• Company completed acquisitions of Memo Therapeutics and Kartos Therapeutics in Q3

Outlook

• Ipsen now sees 2026 total sales growth around 23.0% at CER, up from >20.0%

• Company raises core operating margin to around 39.0% from to >37.0%

• Guidance assumes strong double-digit growth in core portfolio and Somatuline despite generic entry

Result Drivers

• CORE PORTFOLIO AND SOMATULINE - Co said Q3 results were driven by strength of its core portfolio and continued growth of Somatuline, per CEO David Loew

• PIPELINE EXPANSION - Acquisitions of Memo Therapeutics and Kartos Therapeutics in Q3 strengthened Rare Disease and Oncology pipelines

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and 3 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Ipsen SA is €160.00, about 5.1% above its October 21 closing price of €152.20

• The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 13 three months ago

Reuters Recommended Reads

• Oct 20 - France's EssilorLuxottica Q3 revenue rises on wearables, myopia management portfolio growth

• Oct 19 - France's Virbac Q3 revenue rises on strength in Both Companion Animal, Farm Animal segments

• Oct 20 - Novo's CagriSema helped women lose 25% of weight on average, analysis shows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)